394 related articles for article (PubMed ID: 26351386)
1. A Matrix-based Model Predicts Primary Response to Infliximab in Crohn's Disease.
Billiet T; Papamichael K; de Bruyn M; Verstockt B; Cleynen I; Princen F; Singh S; Ferrante M; Van Assche G; Vermeire S
J Crohns Colitis; 2015 Dec; 9(12):1120-6. PubMed ID: 26351386
[TBL] [Abstract][Full Text] [Related]
2. Comparative Effectiveness of Infliximab Versus Adalimumab in Patients with Biologic-Naïve Crohn's Disease.
Benmassaoud A; Al-Taweel T; Sasson MS; Moza D; Strohl M; Kopylov U; Paradis-Surprenant L; Almaimani M; Bitton A; Afif W; Lakatos PL; Bessissow T
Dig Dis Sci; 2018 May; 63(5):1302-1310. PubMed ID: 29243105
[TBL] [Abstract][Full Text] [Related]
3. A Novel Model Based on Serum Biomarkers to Predict Primary Non-Response to Infliximab in Crohn's Disease.
Li L; Chen R; Zhang Y; Zhou G; Chen B; Zeng Z; Chen M; Zhang S
Front Immunol; 2021; 12():646673. PubMed ID: 34367126
[TBL] [Abstract][Full Text] [Related]
4. Benefit of infliximab reintroduction after successive failure of infliximab and adalimumab in Crohn's disease.
Gagniere C; Beaugerie L; Pariente B; Seksik P; Amiot A; Abitbol V; Allez M; Cosnes J; Sokol H
J Crohns Colitis; 2015 Apr; 9(4):349-55. PubMed ID: 25547977
[TBL] [Abstract][Full Text] [Related]
5. Serum Infliximab, Antidrug Antibodies, and Tumor Necrosis Factor Predict Sustained Response in Pediatric Crohn's Disease.
Stein R; Lee D; Leonard MB; Thayu M; Denson LA; Chuang E; Herskovitz R; Kerbowski T; Baldassano RN
Inflamm Bowel Dis; 2016 Jun; 22(6):1370-7. PubMed ID: 27057683
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcome of perianal fistulizing Crohn's disease treated with infliximab.
Bouguen G; Siproudhis L; Gizard E; Wallenhorst T; Billioud V; Bretagne JF; Bigard MA; Peyrin-Biroulet L
Clin Gastroenterol Hepatol; 2013 Aug; 11(8):975-81.e1-4. PubMed ID: 23376316
[TBL] [Abstract][Full Text] [Related]
7. Fecal Calprotectin Pretreatment and Induction Infliximab Levels for Prediction of Primary Nonresponse to Infliximab Therapy in Crohn's Disease.
Beltrán B; Iborra M; Sáez-González E; Marqués-Miñana MR; Moret I; Cerrillo E; Tortosa L; Bastida G; Hinojosa J; Poveda-Andrés JL; Nos P
Dig Dis; 2019; 37(2):108-115. PubMed ID: 30149385
[TBL] [Abstract][Full Text] [Related]
8. Implications of Infliximab Treatment Failure and Influence of Personalized Treatment on Patient-reported Health-related Quality of Life and Productivity Outcomes in Crohn's Disease.
Steenholdt C; Brynskov J; Thomsen OØ; Munck LK; Christensen LA; Pedersen G; Kjeldsen J; Ainsworth MA
J Crohns Colitis; 2015 Nov; 9(11):1032-42. PubMed ID: 26245216
[TBL] [Abstract][Full Text] [Related]
9. Changes in serum trough levels of infliximab during treatment intensification but not in anti-infliximab antibody detection are associated with clinical outcomes after therapeutic failure in Crohn's disease.
Steenholdt C; Bendtzen K; Brynskov J; Thomsen OØ; Munck LK; Christensen LA; Pedersen G; Kjeldsen J; Ainsworth MA
J Crohns Colitis; 2015 Mar; 9(3):238-45. PubMed ID: 25576753
[TBL] [Abstract][Full Text] [Related]
10. Accelerated Step-Up Infliximab Use Is Associated with Sustained Primary Response in Pediatric Crohn's Disease.
Ling J; Buurman D; Ravikumara M; Mews C; Thacker K; Grover Z
Dig Dis Sci; 2018 Apr; 63(4):1003-1010. PubMed ID: 29480415
[TBL] [Abstract][Full Text] [Related]
11. Factors predicting the therapeutic response to infliximab during maintenance therapy in Japanese patients with Crohn's disease.
Matsuoka K; Hamada S; Shimizu M; Nanki K; Mizuno S; Kiyohara H; Arai M; Sugimoto S; Iwao Y; Ogata H; Hisamatsu T; Naganuma M; Kanai T; Mochizuki M; Hashiguchi M
PLoS One; 2018; 13(10):e0204632. PubMed ID: 30286108
[TBL] [Abstract][Full Text] [Related]
12. An Increased Serum N-Terminal Telopeptide of Type I Collagen, a Biochemical Marker of Increased Bone Resorption, Is Associated with Infliximab Therapy in Patients with Crohn's Disease.
Sugimoto K; Ikeya K; Iida T; Kawasaki S; Arai O; Umehara K; Watanabe F; Tani S; Oishi S; Osawa S; Yamamoto T; Hanai H
Dig Dis Sci; 2016 Jan; 61(1):99-106. PubMed ID: 26254083
[TBL] [Abstract][Full Text] [Related]
13. High C-reactive protein in Crohn's disease patients predicts nonresponse to infliximab treatment.
Magro F; Rodrigues-Pinto E; Santos-Antunes J; Vilas-Boas F; Lopes S; Nunes A; Camila-Dias C; Macedo G
J Crohns Colitis; 2014 Feb; 8(2):129-36. PubMed ID: 23932786
[TBL] [Abstract][Full Text] [Related]
14. Influence of nutritional status on the therapeutic effect of infliximab in patients with Crohn's disease.
Sumi R; Nakajima K; Iijima H; Wasa M; Shinzaki S; Nezu R; Inoue Y; Ito T
Surg Today; 2016 Aug; 46(8):922-9. PubMed ID: 26438200
[TBL] [Abstract][Full Text] [Related]
15. Treatment with infliximab for pediatric Crohn's disease: Nationwide survey of Japan.
Hosoi K; Ohtsuka Y; Fujii T; Kudo T; Matsunaga N; Tomomasa T; Tajiri H; Kunisaki R; Ishige T; Yamada H; Arai K; Yoden A; Ushijima K; Aomatsu T; Nagata S; Uchida K; Takeuchi K; Shimizu T
J Gastroenterol Hepatol; 2017 Jan; 32(1):114-119. PubMed ID: 27478130
[TBL] [Abstract][Full Text] [Related]
16. A random forest model predicts responses to infliximab in Crohn's disease based on clinical and serological parameters.
Li Y; Pan J; Zhou N; Fu D; Lian G; Yi J; Peng Y; Liu X
Scand J Gastroenterol; 2021 Sep; 56(9):1030-1039. PubMed ID: 34304688
[TBL] [Abstract][Full Text] [Related]
17. Infliximab for the treatment of Crohn's disease: efficacy and safety in a Chinese single-center retrospective study.
Zhou Y; He H; Wang P; Zhang T; Lin M; Wang H; Nie Y; Chen Y
Eur J Gastroenterol Hepatol; 2015 Nov; 27(11):1270-5. PubMed ID: 26275085
[TBL] [Abstract][Full Text] [Related]
18. Infliximab response associates with radiologic findings in bio-naïve Crohn's disease.
Yueying C; Jing F; Qi F; Jun S
Eur Radiol; 2023 Aug; 33(8):5247-5257. PubMed ID: 36928565
[TBL] [Abstract][Full Text] [Related]
19. Development of a clinical model to predict secondary non-response of infliximab treatment in Crohn's disease.
Xu L; Shen J; Zheng Q
Int J Colorectal Dis; 2020 Nov; 35(11):2019-2026. PubMed ID: 32577870
[TBL] [Abstract][Full Text] [Related]
20. Adalimumab and infliximab are equally effective for Crohn's disease in patients not previously treated with anti-tumor necrosis factor-α agents.
Kestens C; van Oijen MG; Mulder CL; van Bodegraven AA; Dijkstra G; de Jong D; Ponsioen C; van Tuyl BA; Siersema PD; Fidder HH; Oldenburg B;
Clin Gastroenterol Hepatol; 2013 Jul; 11(7):826-31. PubMed ID: 23376000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
